Abstracts

CARDIAC BNP DEFICIENCY RELATES TO EXCESS ADIPOSITY AND METABOLIC PERTURBATIONS IN HIV

Well-treated persons living with HIV(PLWH) at risk for fat dysfunction demonstrate renin-angiotensin-aldosterone system(RAAS) dysregulation. Natriuretic peptides(NP) are key cardiac hormones which serve as negative regulators on the RAAS and play a role in preserving cardiac structure and metabolic homeostasis. In generalized obesity, relative NP deficiency contributes to advanced metabolic risk. We investigated BNP in relation…

ASSOCIATION OF SUBCLINICAL CMV DNA AND IMMUNOLOGIC MARKERS OF CARDIOVASCULAR DISEASE

HIV-CMV co-infected persons are at increased risk of cardiovascular disease (CVD) associated with persistent inflammation. Persons with high interferon (IFN)γ response to CMV have increased numbers of endothelium homing receptor (CX3CR1)- expressing cells that are associated with CVD. Here, we investigated the effect of subclinical CMV replication on these markers. 80 paired PBMC samples were…

LOWER PRETREATMENT GUT INTEGRITY ASSOCIATED WITH FAT GAINS ON ANTIRETROVIRALS

Despite advances in antiretroviral therapy (ART), obesity and insulin resistance remain a threat to treatment success. HIV infection is known to disrupt gut barrier integrity, leading to microbial translocation. Little is known about the differential effect of integrase and protease inhibitors on gut integrity, and the role of gut dysfunction in metabolic complications associated with…

PREVALENCE AND CORRELATES OF HPGV INFECTION AMONG PWID WITH HIV INFECTION IN INDIA

Human Pegivirus (HPgV) shares overlapping transmission routes with HIV as it is transmitted through percutaneous and sexual routes. Previous studies have shown that HPgV infection is associated with reduced disease progression among HIV-infected individuals. However, most of these data are from resource-rich settings with non-clade C HIV infection. We estimate the prevalence of HPgV infection…

ERADICATION OF HCV: EFFECTS ON CARDIOVASCULAR RISK AND PRECLINICAL ATHEROSCLEROSIS

We previously showed that eradication of HCV in HIV/HCV-coinfected patients was associated a near-significant increase in the risk of cardiovascular events (Hepatology 2017; 66:344). We compared changes in 10-year Framingham cardiovascular risk (10y-CVR) and changes in noninvasive tests for preclinical atherosclerosis in coinfected patients with and without SVR receiving anti-HCV therapy (anti-HCV Rx). We performed…